EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).
Punekar S, Hecht J, Smith C, Simeone D, Dorigo O, Boyd L, Kirtane K, Ward J, Locke F, Morelli M, Block M, Eskander R, Langeberg W, Liechty K, Ong G, Go W, Maloney D, Maus M, Welch J, Molina J. EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH). Journal Of Clinical Oncology 2024, 42: tps2699-tps2699. DOI: 10.1200/jco.2024.42.16_suppl.tps2699.Peer-Reviewed Original ResearchChimeric antigen receptorOff-tumor toxicityT-cell therapyCAR-T cell therapyMesothelin expressionT cellsHLA-A*02Solid tumorsNormal cellsChimeric antigen receptor T cellsRecommended phase 2 doseCAR T cell activityLack of tumor-specific targetsNon-small cell lung cancerCryopreserved T cellsMajor body cavitiesPhase 2 doseDose-expansion phaseObjective of Phase 1Tumor-specific targetingCell lung cancerSolid tumor typesFirst-in-humanT cell activationOn-target